|
Recent LSBC Activities
- BIO 2020 Virtual Conference: This year BIO is virtual and as part of the week-long conference LSBC hosted a BC Event with Deputy Minister Fazil Mihlar of the Ministry of Jobs, Economic Development and Competitiveness. The BC event was captured on Zoom and you can watch it here.
Note:When available, going forward, videos of LSBC events will be posted to coincide with our activites
|
|
Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress
VICTORIA, British Columbia-(BUSINESS WIRE)-Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that new subgroup analyses from the completed AURORA pivotal trial of voclosporin were presented.
READ MORE
|
|
Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in Montreal
MONTREAL,
June 8, 2020 /CNW Telbec/ - CTI Life Sciences, along with partners adMare BioInnovations, Domain Therapeutics and PeptiMimesis Pharma, have come together to establish a new
Montreal-based drug discovery and development company, Find Therapeutics, dedicated to the development of the next generation of GPCR allosteric modulators to treat rare diseases.
READ MORE
|
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020
VICTORIA, British Columbia-(BUSINESS WIRE)- Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that additional safety data from the completed AURORA pivotal trial of voclosporin .....
READ MORE
|
|
CSL Behring to Acquire Biotech Company Vitaeris
KING OF PRUSSIA, Pa.
, June 8, 2020 /PRNewswire/ - Global biotherapeutics leader
CSL Behring
announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.
READ MORE
|
DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
SAN DIEGO & PRINCETON, N.J., June 10, 2020 /PRNewswire/ - DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar") and Adgero Biopharmaceuticals Holdings, Inc. ("Adgero") today announced the companies have entered into a definitive merger agreement pursuant to which DelMar, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, will acquire Adgero....
READ MORE
|
Health Research Foundation of Innovative Medicines Canada Chair in Pandemic Preparedness Research
June 11, 2020 | The Health Research Foundation of Innovative Medicines Canada invites applications for the Health Research Foundation of Innovative Medicines Canada Chair in Pandemic Preparedness Research
.
READ MORE
|
Lilly says COVID-19 treatment could be authorized for use as soon as September
June 10, 2020 | VINCENT KESSLER/REUTERS
Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told Reuters on Wednesday.
READ MORE
|
Johnson & Johnson moves up start of coronavirus vaccine human trials to July
June 10, 2020 | Globe and Mail | Johnson & Johnson moved up the start of human clinical trials for its experimental vaccine against the highly contagious coronavirus by two months to the second half of July, as the drugmaker rushes to develop a prevention for COVID-19, the company said on Wednesday.
READ MORE
|
|
EMPLOYMENT OPPORTUNITIES and PROGRAMS
|
|
What could your company do with $20,000 in wage subsidies?
Wage Subsidies for Hiring Young Talent
The Career Starter Program facilitates the transition for youth facing challenges entering the labour market and increases their knowledge of the sector's needs through recent and practical work experience. The program provides 50% of the youth's salary to a maximum of $20,000 in wage subsidies for a 3 to 9-months placement.
Are you eligible?
As a resource to the bio-economy, BioTalent Canada is continuing its operations virtually including accepting wage subsidy applications, and processing claims as quickly as possible. Employers, uncertain if your job qualifies or would like to be pre-qualified before you hire?
Contact:
|
approximately 60,000 visitors a month?
~
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on Biotalent's
The Petri Dish?
After your first five reposts, you will also receive 25% off all job postings on
The Petri Dish!
Want more info? Please contact Sue Callaghan at
|
DUE TO THE COVID 19 VIRUS, LIFESCIENCES BC STAFF ARE WORKING FROM HOME. WE WILL RETURN TO NORMAL WORKING CONDITIONS ONCE GOVERNMENT HAS SAID IT IS SAFE TO DUE SO.
UNTIL THEN, WE ARE ALL REACHABLE BY EMAIL LISTED
HERE
.
|
|
|
|
